Bridging Hematologic Cancer Disparities: A Path to Equity

San Diego, CA US
December 9, 2023

Disparities in hematologic cancers can manifest in various ways, including differences in incidence, access to care, treatment outcomes, and survival rates among diverse population groups. Addressing these disparities is essential for providing equitable patient care and improving overall outcomes.
The gaps observed in cancer care are rooted not only in healthcare accessibility challenges but also in cultural obstacles, entrenched racism, environmental disadvantages, hereditary risk factors, ongoing health complications, and sustained stress due to prejudice and societal exclusion. The intricate interplay of these elements has mainly contributed to the challenge of curbing health discrepancies and achieving a balanced health landscape.
This hematology conference, Bridging Hematologic Cancer Disparities: A Path to Equity, will shed light on a spectrum of topics that delve into the systemic obstacles and racial discrimination causing these health inequities. We aim to spotlight both the problems and potential solutions, emphasizing programs and research that target these cancer care disparities.

Target Audience

  • Hematologists and medical oncologists
  • Hematology/oncology fellows
  • Pharmacists
  • Nurse practitioners/physician assistants

Learning Objectives

By the end of this CME activity, participants will be able to:

  1. Review the disparities in incidence, diagnosis, and outcomes of hematologic malignancies among different population groups.
  2. Describe the social determinants and biological factors contributing to disparities in hematologic cancers.
  3. Identify barriers to care and the impact of these barriers on treatment outcomes.
  4. Implement strategies to promote equitable care for all patients with hematologic malignancies.

 

Course summary
Course opens: 
10/29/2023
Course expires: 
01/27/2024
Event starts: 
12/09/2023 - 5:30pm PST
Event ends: 
12/09/2023 - 8:30pm PST
Cost:
$0.00
Add to calendar: 

December 9th, 2023

All times are listed in Pacific Time (PT)

05:30 PM to 06:00 PM – Networking

06:00 PM – Dinner

06:00 PM to 06:15 PM – Introduction & Welcome - Binay Shah, MD, MHA

06:15 PM to 07:00 PM – Access to bispecifics and cellular therapy panel discussion

Moderator: Martha Pritchett Mims, MD, PhD

Panelists: Srinivas Tantravahi, MBBS, MRCP; Hamza Hashmi, MD; Haifaa Abdulhaq, MD; C. Anthony Blau, MD; Grzegorz S. Nowakowski, MD

07:00 PM to 07:45 PM – Global hematology panel discussion

Moderator: Binay Shah, MD, MHA

Panelists: Steven Kussick, MD, PhD; Siddhartha Ganguly, MD, FACP; Dinesh Pendharkar, MD, PhD, MBA

 

 

The Westin San Diego Gaslamp Quarter
910 Broadway Cir
Del Mar (1st floor)
San Diego, CA 92101
United States
Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno

has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Novartis;.

C. Anthony Blau

has no relevant financial relationships to disclose at this time.

Siddhartha Ganguly, MD, FACP

has a financial relationship (Financial Support) with Astra Zeneca;.
has a financial relationship (Financial Support) with Sanofi Genzyme;.
has a financial relationship (Financial Support) with Kite Pharma;.

Hamza Hashmi, M.D., M.B.B.S.

has a financial relationship (Independent contractor) with KARYOPHARM;.
has a financial relationship (Independent contractor) with AMGEN;.
has a financial relationship (Independent contractor) with JANSSEN;.

Steven Kussick, MD, PhD

has no relevant financial relationships to disclose at this time.

Grzegorz Nowakowski, MD

has a financial relationship (Professional Services) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with Zai Laboratory;.
has a financial relationship (Professional Services) with Constellation Pharmaceuticals;.
has a financial relationship (Professional Services) with Fate Therapeutics ;.
has a financial relationship (Professional Services) with Debiopharm;.
has a financial relationship (Professional Services) with Genentech Inc;.
has a financial relationship (Professional Services) with F Hoffmann-La Roche Limited;.
has a financial relationship (Professional Services) with Daiichi Sankyo, Inc.;.
has a financial relationship (Professional Services) with Bantam Pharmaceutical, LLC;.
has a financial relationship (Professional Services) with Blueprint Medicines Corporation;.
has a financial relationship (Professional Services) with TG Therapeutics, Inc;.
has a financial relationship (Professional Services) with Selvita Inc;.
has a financial relationship (Professional Services) with MorphoSys AG;.
has a financial relationship (Professional Services) with Bristol-Myers Squibb;.
has a financial relationship (Professional Services) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with TG Therapeutics, Inc;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Incyte Corporation;.
has a financial relationship (Professional Services) with Celgene Corporation;.
has a financial relationship (Professional Services) with Seagen;.
has a financial relationship (Professional Services) with Kite Pharma, Inc.;.
has a financial relationship (Professional Services) with Kymera Therapeutics;.
has a financial relationship (Professional Services) with AbbVie Inc.;.
has a financial relationship (Professional Services) with MEI Pharma;.
has a financial relationship (Professional Services) with Ryvu Therapeutics;.
has a financial relationship (Professional Services) with Curis;.
has a financial relationship (Professional Services) with Constellation Pharmaceuticals;.

Dinesh Pendharkar, Director Sarvodaya Cancer Institute, MD Phd FASCO

has no relevant financial relationships to disclose at this time.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Financial Support) with karyopharm therapeutics;.
has a financial relationship (Professional Services) with MorphoSys;.
has a financial relationship (Professional Services) with CTI BioPharma;.
has a financial relationship (Professional Services) with AbbVie;.
Moderator(s)

Martha Mims

has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Stock) with Biogen IDEC;.
has a financial relationship (Stock) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Aveo;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Please contact sponsorships@binayfoundation.org with the subject line "Hematology Disparities Sponsorship at ASH" if you are interested in exhibiting at this meeting.

Price

Cost:
$0.00
Please login or register to take this course.

Free Registration for all Health Care Providers. 

Please contact sponsorships@binayfoundation.org with the subject line "Hematology Disparities Sponsorship at ASH" if you are interested in exhibiting at this meeting.